Pharma Mar Stock Forecast, Price & News

-0.80 (-0.71 %)
(As of 04/9/2021 08:27 PM ET)
Today's Range
Now: $111.50
50-Day Range
MA: $123.30
52-Week Range
Now: $111.50
Volume200 shs
Average Volume1,414 shs
Market Capitalization$2.06 billion
P/E RatioN/A
Dividend YieldN/A
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.
Pharma Mar logo

Industry, Sector and Symbol

Industry Private households
Previous SymbolNASDAQ:PHMMF
Year FoundedN/A



Sales & Book Value

Annual Sales$96.12 million
Book Value$0.45 per share



Market Cap$2.06 billion
Next Earnings DateN/A
OptionableNot Optionable


Pharma Mar SA Bearer Shs Stock , PHMMF
December 28, 2020 |  markets.businessinsider.com
Pharma Mar, S.A. (PHMMF)
May 26, 2020 |  finance.yahoo.com
PharmaMar and Jazz Pharmaceuticals Announce FDA...
February 17, 2020 |  www.benzinga.com
Analysts Expect Breakeven For Pharma Mar, S.A. (BME:PHM)
January 21, 2020 |  finance.yahoo.com
Are Insiders Buying Pharma Mar, S.A. (BME:PHM) Stock?
December 6, 2019 |  finance.yahoo.com
Does Pharma Mar, S.A. (BME:PHM) Have A High Beta?
October 1, 2019 |  finance.yahoo.com
Pharma Mar (BME:PHM) Is Making Moderate Use Of Debt
August 29, 2019 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.48 out of 5 stars

Medical Sector

1611th out of 2,011 stocks

Private Households Industry

300th out of 378 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.80 (-0.71 %)
(As of 04/9/2021 08:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHMMF News and Ratings via Email

Sign-up to receive the latest news and ratings for PHMMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pharma Mar (OTCMKTS:PHMMF) Frequently Asked Questions

Is Pharma Mar a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharma Mar in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Pharma Mar stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PHMMF, but not buy additional shares or sell existing shares.
View analyst ratings for Pharma Mar
or view top-rated stocks.

What stocks does MarketBeat like better than Pharma Mar?

Wall Street analysts have given Pharma Mar a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pharma Mar wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Pharma Mar's stock been impacted by COVID-19?

Pharma Mar's stock was trading at $3.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PHMMF stock has increased by 3,085.7% and is now trading at $111.50.
View which stocks have been most impacted by COVID-19

Who are Pharma Mar's key executives?

Pharma Mar's management team includes the following people:
  • Mr. José María Fernández Sousa-Faro, Founder, Exec. Chairman, CEO & Pres
  • Mr. Pedro Francisco Fernández Puentes, Exec. Vice-Chairman
  • Mr. Juan Carlos-Torres Carretero, Founder (Age 72)
  • Ms. María Luisa de Francia Caballero, Chief Financial Officer
  • Mr. Pascal Besman, Chief Operating Officer
  • Ms. Elena Calleja Crespo, Director of Fin. & Admin.
  • Mr. José Luis Moreno Martinez-Losa, Director of Capital Markets & Investor Relations
  • Ms. Sandra Llamera Sánchez, Global Compliance Head
  • Ms. Maria Concepcion Sanz, Bus. Legal Director
  • Mr. Juan Nogués, Director of Marketing and Sales

Who are some of Pharma Mar's key competitors?

What is Pharma Mar's stock symbol?

Pharma Mar trades on the OTCMKTS under the ticker symbol "PHMMF."

How do I buy shares of Pharma Mar?

Shares of PHMMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharma Mar's stock price today?

One share of PHMMF stock can currently be purchased for approximately $111.50.

How much money does Pharma Mar make?

Pharma Mar has a market capitalization of $2.06 billion and generates $96.12 million in revenue each year. The company earns $-12,740,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Pharma Mar have?

Pharma Mar employs 443 workers across the globe.

What is Pharma Mar's official website?

The official website for Pharma Mar is www.pharmamar.com.

Where are Pharma Mar's headquarters?

Pharma Mar is headquartered at Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770.

How can I contact Pharma Mar?

Pharma Mar's mailing address is Avda. De los Reyes 1 Pol. Ind. La Mina, Madrid U3, 28770. The company can be reached via phone at 34-91-846-6000 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.